Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center

Articles by Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center

Emerging Agents for Heart Failure Treatment

ByJames Januzzi, MD, Massachusetts General Hospital, Harvard Medical School,Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center

May 7th 2021

James Januzzi, MD, and Javed Butler, MD, MPH, MBA, discuss emerging agents, vericiguat and intravenous (IV) iron, in the treatment landscape for heart failure with reduced ejection fraction and advice for community physicians managing patients with heart failure.

Challenges for Achieving Optimal Therapy in HF

ByJames Januzzi, MD, Massachusetts General Hospital, Harvard Medical School,Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center

April 30th 2021

Cardiology experts discuss challenges in achieving the optimal therapy for patients with heart failure and the influence of patient lifestyle and medical factors.

Role of SGLT2 Inhibitor Therapy for HF Treatment

ByJames Januzzi, MD, Massachusetts General Hospital, Harvard Medical School,Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center

April 30th 2021

Insights on approaching the initiation of SGLT2 inhibitors for the treatment of heart failure with reduced ejection fraction.

Evolution of SGLT2 Inhibitors in Treatment Regimens

ByJames Januzzi, MD, Massachusetts General Hospital, Harvard Medical School,Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center

April 23rd 2021

Javed Butler, MD, MPH, MBA, reviews the historical background of using SGLT2 inhibitors and the impact on patients with heart failure with reduced ejection fraction.

Role of MRA Blockers in HF Treatment

ByJames Januzzi, MD, Massachusetts General Hospital, Harvard Medical School,Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center

April 23rd 2021

Evaluating the facilitation of an MRA (mineralocorticoid receptor antagonist) when using an optimal adjuvant medical therapy for the treatment of heart failure.

Target Dose in HF Therapies for Reduced Ejection Fraction

ByJames Januzzi, MD, Massachusetts General Hospital, Harvard Medical School,Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center

April 16th 2021

Contraindications for clinicians to keep in mind when administering sacubitril/valsartan therapy, and an examination of target dose for therapies in heart failure with reduced ejection fraction.

Considering ARNIs as De Novo Therapy in Heart Failure

ByJames Januzzi, MD, Massachusetts General Hospital, Harvard Medical School,Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center

April 16th 2021

Considerations for initiating sacubitril/valsartan as de novo therapy in patients naïve to angiotensin-converting enzyme inhibitors or angiotensin receptor blocker therapies as per the 2021 update of the expert consensus decision pathway document.

Using Sacubitril/Valsartan in Heart Failure Treatment

ByJames Januzzi, MD, Massachusetts General Hospital, Harvard Medical School,Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center

April 9th 2021

A discussion on the safety and efficacy of angiotensin receptor-neprilysin inhibitor (ARNI), sacubitril/valsartan, for the treatment of heart failure.

Evolution of Heart Failure Treatments

ByJames Januzzi, MD, Massachusetts General Hospital, Harvard Medical School,Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center

April 9th 2021

Experts in cardiology provide a brief history on treatments used for heart failure including ACE (angiotensin converting enzyme) inhibitors and beta blockers.

ACC Expert Consensus Decision Pathway for HF Treatment

ByJames Januzzi, MD, Massachusetts General Hospital, Harvard Medical School,Javed Butler, MD, MPH, MBA, University of Mississippi Medical Center

April 2nd 2021

Using the ACC Expert Consensus Decision Pathway documents for the optimization of heart failure treatment and managing the increasing complexity of the disease.